Now Playing
Opinion|Videos|September 27, 2024
GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma
Panelists discuss how their clinical experience with GPRC5D bispecific therapies has been limited or nonexistent due to the novelty of these treatments in multiple myeloma.
Advertisement
Episodes in this series
- Have you had clinical experience with GPRC5D bispecific therapies?
- If so, please share your experience
Advertisement
Related to this article
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.
Full results from the phase 3 CERVINO trial assessing etentamig in relapsed/refractory multiple myeloma will be shared at the 23rd IMS Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
2
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
3
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
4
Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy
5